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COMPOSITIONS AND METHODS FOR 
TREATING YERSINIA PEST IS INFECTION 
RELATED APPLICATIONS 
This application claims priority from US. Provisional 
Application Ser. No. 60/828,895 ?led Oct. 10, 2006, the 
entire disclosure of Which is incorporated herein by this ref 
erence. 
GOVERNMENT INTEREST 
Subject matter described herein Was made With US. Gov 
ernment support under Grant Number AI48491, IUF4 
AI057175, and 5K30HL004163-05 aWarded by the National 
Institute of Allergy and Infectious Diseases of the National 
Institute of Health. The United States government has certain 
rights in the subject matter. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to composi 
tions and methods for preventing and/or treating plague, 
including compositions and methods for preventing and/or 
treating infection by I’ersinia peslis. 
INTRODUCTION AND GENERAL 
CONSIDERATIONS 
I’ersinia peslis is a highly virulent extracellular pathogen, 
Which causes lethal infection in humans and other animals. I’. 
peslis infection causes plague, including bubonic, pneu 
monic, and septicemic plague. The bacterium poses an omi 
nous threat as an agent of bioterrorism. It is highly infectious 
and contagious by aerosol and can kill in as little as tWo days 
after exposure. 
I’. peslis can be categorized into sub-types, including: Anti 
gua, Medievalis, and Orientalis. I’. peslis pathogenicity can be 
blocked by antibodies to tWo protein antigens, the capsule 
subunit Cafl (also knoWn as F1 antigen, or Fraction 1 anti 
gen), and a surface protein called V antigen (also knoWn as 
LcrV). In this regard, compositions including the F1 antigen 
and the V antigen have been studied for use in treating and 
preventing I’. peslis infection. Although such compositions 
have been shoWn to offer modest protection, against some 
strains of I’. peslis, there are many virulent strains of I’. peslis. 
Examples of such strains include, for example, strain KIM of 
the Mediaevalis sub-type, and strain C092 of the Orientalis 
sub-type. Additionally, modi?cations to I’. peslis antigens can 
be made Without destroying virulence. For example, the V-an 
tigen is variable, such that knoWn compositions containing 
the V-antigen may not be fully protective against certain 
modi?ed strains. Furthermore, the F1 antigen is not required 
for virulence in pneumonic plague, and its gene is easily 
deleted, posing the potential of a WeaponiZed Fl-lacking I’. 
peslis against Which knoWn compositions containing F1 anti 
gen are not effective. 
Accordingly, there remains a need in the art for composi 
tions and methods for preventing and/or treating various 
types and strains of I’. peslis infection. 
SUMMARY 
The presently-disclosed subject matter meets some or all of 
the above-identi?ed needs, as Will become evident to those of 
ordinary skill in the art after a study of information provided 
in this document. 
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This Summary describes several embodiments of the pres 
ently-disclosed subject matter, and in many cases lists varia 
tions and permutations of these embodiments. This Summary 
is merely exemplary of the numerous and varied embodi 
ments. Mention of one or more representative features of a 
given embodiment is likeWise exemplary. Such an embodi 
ment can typically exist With or Without the feature(s) men 
tioned; likeWise, those features can be applied to other 
embodiments of the presently-disclosed subject matter, 
Whether listed in this Summary or not. To avoid excessive 
repetition, this Summary does not list or suggest all possible 
combinations of such features. 
The presently-disclosed subject matter includes composi 
tions and methods for treating a I’ersinia peslis (I’. peslis) 
infection (or plague resulting from such an infection). Com 
positions and methods of the presently-disclosed subject mat 
ter can be used for inducing an immune response in a subject. 
In some embodiments, compositions include an isolated 
polypeptide molecule comprising a sequence at least 80%, 
85%, 90%, or 95% identical to SEQ ID NO: 1, or a functional 
fragment thereof. In some embodiments, the isolated 
polypeptide molecule comprises a sequence at least 80%, 
85%, 90%, or 95% identical to SEQ ID NO: 3. In some 
embodiments, the isolated polypeptide molecule comprises 
the sequence of SEQ ID NO: 3. 
In some embodiments, compositions include an isolated 
polypeptide molecule comprising a sequence at least 80%, 
85%, 90%, or 95% identical to an amino acid sequence 
including residues 137-345 of SEQ ID NO: 1. In some 
embodiments, compositions include an isolated polypeptide 
molecule comprising a sequence at least 80%, 85%, 90%, or 
95% identical to an amino acid sequence including residues 
137-345 of SEQ ID NO: 1. In some embodiments, composi 
tions include an isolated polypeptide molecule comprising a 
sequence at least 80%, 85%, 90%, or 95% identical to an 
amino acid sequence including residues 32-345 of SEQ ID 
NO: 1. 
In some embodiments, compositions include an isolated 
polypeptide molecule comprising an amino acid sequence 
including residues 32-345 of SEQ ID NO: 1. In some embodi 
ments, compositions include an isolated polypeptide mol 
ecule comprising an amino acid sequence including residues 
32-409 of SEQ ID NO: 1. In some embodiments, composi 
tions include an isolated polypeptide molecule comprising an 
amino acid sequence including residues 32-409 of SEQ ID 
NO: 1. 
In some embodiments, compositions include an isolated 
polypeptide molecule comprising a sequence at least about 
80%, 85%, 90%, or 95% identical to an amino acid sequence 
ofSEQ ID NO: 1, Whereinup to about 5, 10, 15, 20, 25, 30, 50, 
125, or 150 amino acids are truncated from the N-terminus of 
SEQ ID NO: 1. In some embodiments, the isolated polypep 
tide molecule comprises at least about 200, 210, 225, 235, 
245, 255, 265, 275, 285, 295, 300, 325, 350 or 375 amino 
acids of SEQ ID NO: 1. 
In some embodiments, compositions include an isolated 
polypeptide molecule comprising a sequence at least about 
80%, 85%, 90%, or 95% identical to an amino acid sequence 
of SEQ ID NO: 1, Wherein up to about 10, 50, 75, 100, 150, 
175, 200, 225, 250, 275, 300, 325, 350, or 400 amino acids are 
truncated from the C-terminus of SEQ ID NO: 1. In some 
embodiments, the isolated polypeptide molecule comprises 
at least about 200, 210, 225, 235, 245, 255, 265, 275, 285, 
295, 300, 325,350 or 375 amino acids of SEQ ID NO: 1. 
In some embodiments, compositions comprise anpolypep 
tide molecule encoded by a nucleotide sequence at least about 
80, 85, 90, or 95% identical to SEQ ID NO: 2, or a subse 
US 7,815,911 B1 
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quence thereof. The encoded polypeptide has improved 
immune response activity relative to, or has all or some of the 
immune response activity of, a polypeptide encoded by a 
nucleotide sequence of SEQ ID NO: 2. In some embodi 
ments, the polypeptide molecule is encoded by a subsequence 
of the nucleotide sequence of SEQ ID NO: 2, Wherein up to 
about 15, 30, 45, 60, 75, 90, 150, 375, or 450 nucleotide 
residues are truncated from the 5' terminus of SEQ ID NO: 2. 
In some embodiments, the polypeptide molecule is encoded 
by a subsequence of the nucleotide sequence of SEQ ID NO: 
2, Wherein up to about 30, 150,225,300, 450, 525, 600, 675, 
750, 825, 900, 975, 1050, or 1200 nucleotide residues are 
truncated from the 3' terminus of SEQ ID NO: 2. 
In some embodiments, compositions include a conserva 
tively-substituted variant of the polypeptide molecule of SEQ 
ID NO: 1, or functional fragments thereof. In some embodi 
ments, compositions include a conservatively-substituted 
variant of the polypeptide molecule of SEQ ID NO: 3, or 
functional fragments thereof. 
In some embodiments, the polypeptide molecule includes 
the amino acid sequence of SEQ ID NO: 1, or a subsequence 
thereof, With up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 
25 conservative amino acid substitutions. In some embodi 
ments, the polypeptide molecule includes the amino acid 
sequence of SEQ ID NO: 3, or a subsequence thereof, With up 
to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or 25 conservative 
amino acid substitutions. In some embodiments, the conser 
vative amino acid substitutions are at or betWeen residues 
346-622 of the YadC polypeptide of SEQ ID NO: 1, or a 
subsequence thereof. In some embodiments, the polypeptide 
molecule includes the amino acid sequence of SEQ ID NO: 1, 
or a subsequence thereof, With up to about 1, 2, 3, 4, or 5 
conservative amino acid substitutions are at or betWeen resi 
dues 32-345 of the YadC polypeptide of SEQ ID NO: 1, or a 
subsequence thereof. 
In some embodiments, compositions induce an immune 
response in a subject against Fl-positive and Fl-negative 
strains of I’. peslis. In some embodiments, compositions 
induce an immune response in a subject against Fl-negative 
strains of I’. peslis. In some embodiments, the subject is in 
need of treatment for a I’. peslis infection. In some embodi 
ments, the subject is susceptible to I’. peslis infection. 
In some embodiments, methods include administering to a 
subject a composition including a YadC polypeptide, as 
described herein. The composition can be administered in an 
amount su?icient to induce an immune response in the sub 
ject. The presently-disclosed subject matter includes methods 
for treating a Yersinia peslis (1’. peslis) infection and/or treat 
ing a plague resulting from such an infection, including 
administering to the subject an effective amount of a compo 
sition including a YadC polypeptide, as described herein. In 
some embodiments, methods include introducing into a sub 
ject a composition comprising an isolated polypeptide mol 
ecule comprising an amino acid sequence of SEQ ID NO: 1, 
or a functional fragment thereof. In some embodiments, 
methods include introducing into a subject a composition 
comprising an isolated polypeptide molecule comprising an 
amino acid sequence of SEQ ID NO: 3, or a functional frag 
ment thereof. In some embodiments, methods include intro 
ducing into a subject a composition comprising a sequence at 
least 80, 85, 90, or 95% identical to SEQ ID NO: 1, or a 
functional fragment thereof. In some embodiments, methods 
include introducing into a subject a composition comprising 
a sequence at least 80, 85, 90, or 95% identical to SEQ ID NO: 
3, or a functional fragment thereof. In some embodiments, 
methods include introducing into the subject a composition 
comprising an isolated polypeptide molecule comprising the 
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sequence ofSEQ ID NO: 1With up to about 1, 2, 3, 4, 5, 6, 7, 
8, 9, 10, 15, 20, or 25 conservative amino acid substitutions, 
or a functional fragment thereof. In some embodiments, 
methods include introducing into the subject a composition 
comprising an isolated polypeptide molecule comprising the 
sequence ofSEQ ID NO: 3 With up to about 1, 2, 3, 4, 5, 6, 7, 
8, 9, 10, 15, 20, or 25 conservative amino acid substitutions, 
or a functional fragment thereof. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic representation of the predicted struc 
ture of YadB and YadC. 
FIG. 2 is a graph depicting the results of a study Wherein 
immuniZed mice Were intravenously challenged With 1’. pes 
Zis. There Was no protection for those immunized With buffer 
alone (Buffer), full protection for HT-LcrV-immuniZed mice 
(LcrV), and partial protection for GST-YadCl37_4O9-immu 
niZed mice (YadC). 
FIG. 3 is a graph depicting the results of a study Wherein 
immuniZed mice Were intranasally challenged With 1’. peslis. 
87% of GST-YadCl37_4O9-immuniZed mice survived pneu 
monic plague, as compared to the GST-immuniZed control 
group (0 surviving mice) and the HT-LcrV-immuniZed group, 
Where 50% survived. 
FIGS. 4A-4D are a series of bar graphs depicting periph 
eral macrophage (PBM) cytokine response. GST-YadCl37_ 
409 leads to increased IL-1, IL-6 and TNF-ot production When 
compared to HT-LcrV. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: 1 is an amino acid sequence for a YadC 
polypeptide; 
SEQ ID NO: 2 is a nucleotide sequence encoding the YadC 
polypeptide of SEQ ID NO: 1; 
SEQ ID NO: 3 is an amino acid sequence for an exemplary 
fragment of the YadC polypeptide of SEQ ID NO: 1; and 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently 
disclosed subject matter are set forth in this document. Modi 
?cations to embodiments described in this document, and 
other embodiments, Will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the speci?c details of the described exemplary 
embodiments, is provided primarily for cleamess of under 
standing and no unnecessary limitations are to be understood 
therefrom. In case of con?ict, the speci?cation of this docu 
ment, including de?nitions, Will control. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to Which the presently 
disclosed subject matter belongs. Although any methods, 
compositions, and materials similar or equivalent to those 
described herein can be used in the practice or testing of the 
presently-disclosed subject matter, representative methods, 
compositions, and materials are noW described. 
FolloWing long-standing patent laW convention, the terms 
“a”, “an”, and “the” refer to “one or more” When used in this 
application, including the claims. Thus, for example, refer 
ence to “a cell” includes a plurality of such cells, and so forth. 
US 7,815,911 B1 
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Unless otherwise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the speci?cation and claims are to be 
understood as being modi?ed in all instances by the term 
“about”. Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this speci?cation and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
subject matter. 
As used herein, the term “about,” When referring to a value 
or to an amount of mass, Weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments 120%, in some embodiments 110%, in some 
embodiments 15%, in some embodiments 11%, in some 
embodiments 10.5%, and in some embodiments 10.1% from 
the speci?ed amount, as such variations are appropriate to 
perform the disclosed method. 
The presently-disclosed subject matter includes composi 
tions and methods for inducing an immune response in a 
subject. The presently-disclosed subject matter further 
includes antibodies, such as humaniZed monoclonal antibod 
ies, that recogniZe epitopes of YadC, and active antibody 
fragments. As used herein, the term “immune response” 
refers to a humoral and/or cellular immune response, in a 
subject, to an introduction of a composition described herein, 
Which response interferes With or inhibits the virulence, activ 
ity, spread, and/or groWth of a Yersinia peslis (1’. peslis). 
Examples of immune responses include the stimulation of 
antibodies, T-cells, macrophages, B-cells, dendritic cells, etc. 
These responses can be measured routinely, as Will be under 
stood by those of ordinary skill in the art. As used herein, an 
immune response activity refers to the ability of a compound 
to elicit an immune response. 
As used herein, the term “subject” refers to both human and 
animal subjects. Thus, veterinary therapeutic uses are pro 
vided in accordance With the presently-disclosed subject mat 
ter. As such, the presently disclosed subject matter provides 
for the treatment of mammals such as humans, as Well as 
those mammals of importance due to being endangered, such 
as Siberian tigers; of economic importance, such as animals 
raised on farms for consumption by humans; and/ or animals 
of social importance to humans, such as animals kept as pets 
or in ZOOS. Examples of such animals include but are not 
limited to: carnivores such as cats and dogs; sWine, including 
pigs, hogs, and Wild boars; ruminants and/ or ungulates such 
as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels; 
and horses. Also provided is the treatment of birds, including 
the treatment of those kinds of birds that are endangered 
and/or kept in Zoos, as Well as foWl, and more particularly 
domesticated foWl, i.e., poultry, such as turkeys, chickens, 
ducks, geese, guinea foWl, and the like, as they are also of 
economic importance to humans. Thus, also provided is the 
treatment of livestock, including, but not limited to, domes 
ticated sWine, ruminants, ungulates, horses (including race 
horses), poultry, and the like. 
The compositions and methods of the presently-disclosed 
subject matter can be used for treating a Yersinia peslis (1’. 
peslis) infection and/or treating a plague resulting from such 
an infection. As used herein, the terms “treatment” and “treat 
ing” relate to any treatment of a I’. peslis, including but not 
limited to prophylactic treatment (i.e., pre-infection), and 
therapeutic treatment (i.e., post-infection). The terms “treat 
ment” or “treating” include: preventing the development of a 
Ypeslis infection and/or plague occurring in a subject; reduc 
ing the severity of a Ypeslis infection and/ or plague occurring 
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in a subject; and/or ameliorating or relieving the symptoms 
associated With a I’. peslis infection and/or plague occurring 
in a subject. 
In some embodiments, the compositions and methods of 
the presently-disclosed subject matter canbe used for treating 
an Fl-positive (131+) or an Fl-negative (Fl') 1’. peslis strain. 
In some embodiments, the compositions and methods can be 
used for treating a I’. peslis C092 strain. In some embodi 
ments, the compositions and methods can be used for treating 
an F1“ 1’. peslis strain. In some embodiments, the composi 
tions and methods can be used for treating an Fl'I’. peslis 
C092 strain. Embodiments of the compositions and methods 
can be used for treating any I’. peslis strain having a yadC 
gene. 
In some embodiments, compositions include an isolated 
YadC polypeptide. (YadC is also knoWn as YP01388 of I’. 
peslis C092). In some embodiments, compositions include at 
least tWo isolatedYadC polypeptides. In some embodiments, 
compositions can include a YadC polypeptide, and at least 
one additional compounds for treating I’. peslis infection, for 
example, one or more of the compounds identi?ed in one of 
the folloWing references, each of Which is incorporated herein 
by this reference: U.S. Pat. Nos. 3,137,629; 5,985,285; 6,638, 
510; 6,706,522; and 6,964,770; and Us. Patent Publication 
Nos: 2004/0151727; 2005/0136075; 2005/0220797; and 
2005/0232940; and PCT Publication Nos: W095/18231; 
W095/24475; W02004/019980; W02005/023205; and 
W02005/120561. 
The terms “polypeptide, protein,” and “peptide” refer to 
a polymer of the 20 protein amino acids, or amino acid ana 
logs, regardless of its siZe or function. Although “protein” is 
often used in reference to relatively large polypeptides, and 
“peptide” is often used in reference to small polypeptides, 
usage of these terms in the art overlaps and varies. Therefore, 
the terms “protein,” “polypeptide,” and “peptide” are used 
interchangeably herein, unless otherWise noted. Exemplary 
polypeptides include gene products, naturally occurring pro 
teins, homologs, orthologs, paralogs, fragments and other 
equivalents, variants, and analogs of the foregoing. The term 
“isolated”, When used in the context of an isolated polypep 
tide, is a polypeptide that, by the hand of man, exists apart 
from its native environment and is therefore not a product of 
nature. An isolated polypeptide can exist in a puri?ed form or 
can exist in a non-native environment. 
As used herein, the term “fragment” refers to a sequence 
that comprises a subset of another sequence. When used in the 
context of an amino acid sequence, the terms “fragment” and 
“subsequence” are used interchangeably. A fragment or sub 
sequence of an amino acid sequence can be any number of 
residues that is less than that found in a reference polypeptide, 
and can include, but is not limited to, domains, features, 
repeats, etc. Also, it is understood that a fragment or subse 
quence of an amino acid sequence need not comprise the 
entirety of the amino acid sequence of the domain, feature, 
repeat, etc. A fragment can also be a “functional fragment,” in 
Which the fragment retains some or all of the activity of the 
reference polypeptide as described herein. For example, a 
functional fragment of a reference polypeptide that is a I’. 
peslis antigen can retain some or all of the immune response 
activity of the reference polypeptide. 
The terms “variant” and “modi?ed,” When used to describe 
polypeptide refer to a polypeptide that is different from a 
reference polypeptide as a result of an intentional manipula 
tion of the amino acid sequence of the polypeptide, or the 
nucleic acid sequence encoding the amino acid sequence of 
the polypeptide. For example, a modi?ed polypeptide or 
polypeptide variant can contain at least one amino acid sub 
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stitution relative to a reference polypeptide. In some embodi 
ments, a modi?ed polypeptide can include one or more addi 
tions and/ or deletions or relative to the amino acid sequence 
of the reference polypeptide, so long as the modi?edpolypep 
tide maintains some or all of the activity of the reference 
polypeptide as described herein. 
The term “conservatively substituted variant” refers to a 
polypeptide comprising an amino acid sequence that differs 
from a reference polypeptide by one or more conservative 
amino acid substitution, and maintains some or all of the 
activity of the reference polypeptide as described herein. A 
“conservative amino acid substitution” is a substitution of an 
amino acid residue With a functionally similar residue. 
Examples of conservative substitutions include the substitu 
tion of one non-polar (hydrophobic) residue such as isoleu 
cine, valine, leucine or methionine for another; the substitu 
tion of one polar (hydrophilic) residue for another such as 
betWeen arginine and lysine, betWeen glutamine and aspar 
agine, betWeen threonine and serine; the substitution of one 
basic residue such as lysine or arginine for another; or the 
substitution of one acidic residue, such as aspartic acid or 
glutamic acid for another; or the substitution of one aromatic 
residue, such as phenylalanine, tyrosine, or tryptophan for 
another. The phrase “conservatively substituted variant” also 
includes polypeptides Wherein a residue is replaced With a 
chemically derivatiZed residue, provided that the resulting 
polypeptide maintains some or all of the activity of the refer 
ence polypeptide as described herein. 
“Percent identity,” or “percent homology” When used 
herein to describe to an amino acid sequence, relative to a 
reference sequence, can be determined using the formula 
described by Karlin andAltschul (Proc. Natl. Acad. Sci. USA 
87: 2264-2268, 1990, modi?ed as in Proc. Natl. Acad. Sci. 
USA 90:5873-5877, 1993). Such a formula is incorporated 
into the basic local alignment search tool (BLAST) programs 
ofAltschul et al. (J. Mol. Biol. 215: 403-410, 1990). To obtain 
gapped alignments for comparison purposes, Gapped 
BLAST is utiliZed as described in Altschul, et al. (Nucleic 
Acids Res. 25: 3389-3402, 1997). When utiliZing BLAST 
and Gapped BLAST programs, the default parameters of the 
respective programs (e. g., XBLAST) are used. 
In some embodiments of the presently-disclosed subject 
matter, a composition for inducing an immune response in a 
subject comprises an isolated polypeptide molecule compris 
ing an amino acid sequence encoded by a nucleotide 
sequence of SEQ ID NO: 2. In some embodiments, the com 
position for inducing an immune response in a subject com 
prises an isolated polypeptide molecule comprising an amino 
acid sequence encoded by a subsequence of the nucleotide 
sequence of SEQ ID NO: 2, so long as the encoded polypep 
tide has improved immune response activity relative to, or has 
all or some of the immune response activity of, a polypeptide 
encoded by a nucleotide sequence of SEQ ID NO: 2. In some 
embodiments, the isolated polypeptide molecule comprises 
an amino acid sequence encoded by a fragment of the nucle 
otide sequence ofSEQ ID NO: 2, Wherein up to about 15, 30, 
45, 60, 75, 90, 150, 375, or 450 nucleotide residues are trun 
cated from the 5' terminus of SEQ ID NO: 2, and/or up to 
about 30, 150, 225, 300, 450, 525, 600, 675, 750, 825, 900, 
975, 1050, or 1200 nucleotide residues are truncated from the 
3' terminus of SEQ ID NO: 2. 
In some embodiments, the YadC polypeptide of the com 
positions includes a polypeptide having an amino acid 
sequence as set forth in SEQ ID NO: 1, or a functional 
fragment thereof. For example, in some embodiments, the 
polypeptide molecule comprises the amino acid sequence 
including amino acid residues 137-409 of YadC, Which frag 
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ment is set forth in SEQ ID NO: 3. For another example, in 
some embodiments, the polypeptide molecule comprises the 
amino acid sequence including amino acid residues 137-345 
of YadC. For another example, in some embodiments, the 
polypeptide molecule comprises the amino acid sequence 
including amino acid residues 32-345 of YadC. For another 
example, in some embodiments, the polypeptide molecule 
comprises the amino acid sequence including amino acid 
residues 32-409 ofYadC. In some embodiments the polypep 
tide molecule comprises a fragment of SEQ ID NO: 1, 
Wherein up to about 5, 10, 15, 20, 25, 30, 50, 125, or 150 
amino acids are truncated from the N-terminus of SEQ ID 
NO: 1 and/or Wherein up to about 10, 50, 75, 100, 150, 175, 
200, 225, 250, 275, 300, 325, 350, or 400 amino acids are 
truncated from the C-terminus of SEQ ID NO: 1. In some 
embodiments, the polypeptide molecule comprises at least 
about 200, 210, 225, 235, 245, 255, 265, 275, 285, 295, 300, 
325, 350 or 375 amino acids of SEQ ID NO: 1. 
In some embodiments, the YadC polypeptide is a variant, 
such as a conservatively-substituted variant, of a polypeptide 
having the amino acid sequence of SEQ ID NO: 1, or a 
sub sequence thereof. For example, in some embodiments, the 
YadC polypeptide is a conservatively-substituted variant hav 
ing the amino acid sequence of SEQ ID NO: 1, or a subse 
quence thereof, With up to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 
20, or 25 conservative amino acid substitutions. In some 
embodiments, the YadC polypeptide is a conservatively-sub 
stituted variant of a polypeptide having the amino acid 
sequence of SEQ ID NO: 3. In some embodiments, up to 
about 1, 2, 3, 4, or 5 amino acid substitutions are betWeen 
amino acid residues 32-345 of the YadC polypeptide of SEQ 
ID NO: 1, or a subsequence thereof. In some embodiments, 
the amino acid substitutions are primarily betWeen amino 
acid residues 346-622 of the YadC polypeptide of SEQ ID 
NO: 1, or a subsequence thereof. In some embodiments, all of 
the amino acid substitutions are betWeen amino acid residues 
346-622 of the YadC polypeptide of SEQ ID NO: 1, or a 
subsequence thereof. Variants can have improved immune 
response activity relative to, or can maintain some or all of the 
immune response activity of the polypeptide having the 
amino acid sequence of SEQ ID NO: 1. 
In some embodiments, the YadC polypeptide is a modi?ed 
polypeptide, relative to the polypeptide having the amino acid 
sequence of SEQ ID NO: 1, or a subsequence thereof. Such 
modi?ed polypeptides can have improved immune response 
activity relative to, or maintain some or all of the immune 
response activity of, the polypeptide having the amino acid 
sequence of SEQ ID NO: 1. In some embodiments, the YadC 
polypeptide includes a polypeptide having 80%, 85%, 90%, 
or 95% identity to a polypeptide having the amino acid 
sequence of SEQ ID NO: 1, or a subsequence thereof, so long 
as the polypeptide has improved immune response activity 
relative to, or maintain some or all of the immune response 
activity of, the polypeptide having the amino acid sequence of 
SEQ ID NO: 1. 
In some embodiments of the presently-disclosed subject 
matter, the compositions can be provided in a formulation 
appropriate for administration to a subject, as Will be under 
stood by those of ordinary skill in the art. For example, in 
some embodiments, the compositions can be provided in as a 
liquid solution or a suspension, suitable for injection. In some 
embodiments, solid forms of the compositions that are suit 
able for solution in, or suspension in, liquid prior to injection 
can be provided. In some embodiments, compositions can be 
mixed With excipients, such as, for example, Water, saline, 
dextrose, glycerol, ethanol, and combinations thereof. In 
some embodiments, formulations can include one or more 
US 7,815,911 B1 
adjuvants. In some embodiments, the adjuvant is a aluminum 
hydroxide, e. g., aluminum hydroxide gel known as ALHY 
DROGEL® (E. M. Sergeant Pulp & Chemical Co. (Clifton, 
N.J.)). Other suitable adjuvants for use in the practice of the 
present subject matter include, but are not limited to polymers 
of acrylic or methacrylic acid, maleic anhydride and alkenyl 
derivative polymers, immunostimulating sequences (ISS), 
such as oligodeoxyribonucleotide sequences having one or 
more non-methylated CpG units, cation lipids containing a 
quaternary ammonium salt, cytokines, and aluminum phos 
phate. 
The presently-disclosed subject matter includes methods 
for inducing an immune response in a subject, including 
administering to a subject a composition including a YadC 
polypeptide, as described above. The composition can be 
administered in an amount su?icient to induce an immune 
response in the subject. The presently-disclosed subject mat 
ter includes methods for treating a Yersinia pestis (1’. pestis) 
infection and/or treating a plague resulting from such an 
infection, including administering to the subject an effective 
amount of a composition including a YadC polypeptide, as 
described above. 
As used herein, the term “effective amount” refers to a 
dosage su?icient to elicit an immune response. The exact 
amount that is required Will vary from subject to subject, 
depending on the species, age, and general condition of the 
subject, the particular carrier or adjuvant being used, mode of 
administration, and the like. As such, the effective amount 
Will vary based on the particular circumstances, and an appro 
priate effective amount can be determined in a particular case 
by one of ordinary skill in the art using only routine experi 
mentation. 
For additional guidance regarding formulation and dose, 
see BerkoW et al., (1997) The Merck Manual of Medical 
Information, Home ed. Merck Research Laboratories, White 
house Station, N.J.; Goodman et al., (2006) Goodman & 
Gilman's the Pharmacological Basis of Therapeutics, 11th 
ed. McGraW-Hill Health Professions Division, NeW York; 
Ebadi, (1998) CRC Desk Reference ofClinical Pharmacol 
ogy. CRC Press, Boca Raton, Fla.; KatZung, (2007) Basic & 
Clinical Pharmacology, 10th ed. Lange Medical Books/ 
McGraW-Hill Medical Pub. Division, NeW York; Remington 
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et al., (1990) Remington's Pharmaceutical Sciences, 18th ed. 
Mack Pub. Co., Easton, Pa.; and Speight et al., (1 997) Avery's 
Drug Treatment: A Guide to the Properties, Choice, T hera 
peutic Use and Economic Value ofDrugs in Disease Man 
agement, 4th ed. Adis International, Auckland/ Philadelphia. 
In some embodiments, compositions can further include 
additional compounds for treating I’. pestis infection, for 
example, one or more of the compounds identi?ed in one of 
the folloWing references, each of Which is incorporated herein 
by this reference: US. Pat. Nos. 3,137,629; 5,985,285; 6,638, 
510; 6,706,522; and 6,964,770; and US. Patent Publication 
Nos: 2004/0151727; 2005/0136075; 2005/0220797; and 
2005/0232940; and PCT Publication Nos: W095/18231; 
W095/24475; W02004/019980; W02005/023205; and 
W02005/120561. 
The presently-disclosed subject matter is further illustrated 
by the folloWing speci?c but non-limiting examples. The 
folloWing examples may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
presently-disclosed subject matter. 
EXAMPLES 
Bacterial strains and plasmids. I’. pestis C099-3015 strains 
Were groWn in Heart Infusion Broth (Difco laboratories, 
Detroit, Mich.) supplemented With 2.5 mM CaCl2 and 0.2% 
xylose (sHIB) on sHIB agar. E. coli strains Were groWn in 
Luria-Bertani broth (LB) or on LB-based agar. The bacterial 
strains and plasmids used in studies described herein are set 
forth in Table 1. Antibiotics Were used at the folloWing con 
centrations during genetic constructions: carbenicillin (Cb), 
100 ug/ml; kanamycin, 25 ug/ml chloramphenicol, 25 ug/ml. 
Cb Was used at 50 ug/ml for groWth of I’. pestis strains con 
taining pCD2Ap. The presence of the pigmentation locus 
(Perry 1997) Was con?rmed by the formation of red colonies 
on Congo Red agar (Surgalla 1969). The presence of a func 
tional Lcr virulence plasmid Was con?rmed by absence of 
groWth at 37° C. on sHIB agar containing 20 mM MgCl2 and 
20 mM sodium oxalate (Mg0x plates) and by assaying 
expression and secretion ofY ops during groWth in the de?ned 
medium TMH (Straley 1986) With and Without 2.5 mM 
CaCl2. 
TABLE 1 
Bacterial Strains and Plasmids Used in This Study. 
Strain or Plasmid Key Properties Source or Reference 
If pestis 
C099-3015 
C099-3015.S2 
Wildtype strain; subclone of C092; molecular grouping 1.0RI. 
C092 Pgm” Lcr’ Aca?, pPst; Fl’ derivative made by allelic 
CDC Ft. Collins 
Spencer Leigh 
exchange into avirulent Lcr’ Fl” I’. pestis C099-3015 obtained 
from Scott Bearden (CDC Ft. Collins); entire ca? coding sequence 
and 12 upstream bp deleted. 
C099-3015.S5 C092 Apgm Lcr” pFra, pPst; conditionally virulent“ Apgm Scott Bearden 
derivative of C099-3015. 
C099-3015.S6 Forman 2006 
made from C099-3015.S5 by allelic exchange; used as source of 
pCD2Ap for electroporation into Lcr’ strains to reconstitute 
potential virulence. 
C099-3015.S7 C092 Apgm Lcr” Aca?, pPst; Fl’ Apgm attenuated strain made This Study 
from C099-3015.S5 by allelic exchange. 
C099-3015.S9 C092 Pgm” Lcr” Aca?, pPst; reconstituted Lcr” Fl’ conditionally This Study 
virulentl7 strain made by allelic exchange. 
E. coli 
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Bacterial Strains and Plasmids Used in This Study. 
Strain or Plasmid Key Properties Source or Reference 
DH50L end-1 hsdR17(rk-mk+) supE44 thi-1 recA1 gyrA (Nalr) relAl Life Technologies, 
A(lacIZYA-argF)U169 deoR (<I>80dlacA (lacZ)M15). Gaithersburg MD 
Plasmids 
pKD3 Template plasmid; cat ?anked by FRT sites; Cm’Ap’ Datsenko 2000 
pKD46 Red recombinase expression plasmid; Apr. Datsenko 2000 
pCP20 Suicide plasmid With temperature-sensitive replication and Datsenko 2000 
thermally induced expression of FLP recombinase; Ap’Cmr 
pHT-V PCR-ampli?ed lcrV cloned into pProEX-l; expresses full-length Fields 1999 
LcrV With a His6—containing 23-residue N-terminal leader 
sequence (HT-LcrV). 
pGEX—YadC137,4O9 Sequence encoding amino acids 137-409 ofYadC in pGEX-3X; Forman 2006 
expresses GS T—YadC1374O9. 
‘Tull virulence is conditional on intravenous route of infection (Perry 1997). 
bFull virulence is conditional on intranasal route ofinfection (Davis 1996). 
Production of the protein capsule F1 Was abolished by 
deleting the caf1 gene. Primers Were used to generate a PCR 
fragment containing the FRP site-?anked cat gene from 
pKD3 ?anked by caf1 sequence, and caf1 Was deleted by 
allelic exchange mediated by the Red and F1p recombinases 
as described in Datsenko, 2000. The resulting deletion started 
at —12 by upstream of the caf1 translation initiation codon 
through the last translated codon. The absence of F1 expres 
sion Was veri?ed by immunoblot of 37° C.-groWn yersiniae 
using the monoclonal antibody YPF1 (Research Diagnostics, 
Inc., Flanders, N.J.), and the absence of cat in the ?nal strain 
Was con?rmed by PCR and by inability to groW on chloram 
phenicol-containing plates. 
Virulence Was reconstituted in BSL3 containment With 
select-agent security by introducing pCD2Ap by electropo 
ration. Brie?y, 1’. peslis CO99-3015.S2 Was electroporated 
With plasmid DNA from 1’. peslis CO99-3015.S6, that con 
tained the 1’. peslis plasmids pFra (110 kb) and pPst (9 kb) 
(Perry 1997) in addition to pCD2Ap. Their presence in the 
transformation Would not pose a problem since the recipient 
strains already contained copies of these tWo plasmids. 
Transformed strains Were selected for Cb-resistance and 
screened for the Pgm+ and Lcr+ phenotypes on agar media. 
Individual isolates that passed these tests Were then subcul 
tured tWo times in 3 ml TMH+Cb at 26° C. for a total of 24 
hours prior to the experiment. The cultures Were subcultured 
a third time into TMH With or Without 2.5 mM CaCl2 and 
alloWed to groW for an additional tWo hours at 26° C. FolloW 
ing this, each culture Was shifted to 37° C. and permitted to 
groW another four hours. A 500-111 sample of each culture Was 
removed and brie?y placed on ice to aid cellular aggregation. 
Cells Were pelleted in a microcentrifuge at room temperature 
(RT) for 10 min. The top 250 pl of supernatant Was removed, 
transferred to a microcentrifuge tube containing trichloroace 
tic acid to a ?nal concentration of 5%, and incubated over 
night at 4° C. to precipitate secreted proteins. The rest of the 
supernatant Was discarded. The precipitated proteins Were 
collected by centrifugation at RT. Pellets of Whole cells and of 
secreted proteins Were suspended in lysis loading buffer (400 
mM TrisCl, pH 6.8, 25% glycerol, 8% SDS, 5% dithiothrei 
tol, 0.4% bromophenol blue) to a concentration correspond 
ing to a culture OD620 of 2.0 and heated to 95° C. for 15 
minutes. Half of each heat-treated sample Was plated and 
incubated for 5 days at 28° C. to ensure that no viable cells 
remained prior to removing the samples from the contain 
ment facility. 
20 
30 
35 
40 
45 
50 
55 
60 
65 
The resultant cellular extracts and supernatant proteins 
Were then analyzed by immunoblot for the presence of 
secreted LcrV andYopM, as described in Wulff- Strobel 2001, 
to determine Whether the type three secretion system Was 
fully functional. Several isolated colonies Were then pooled 
and stocked. 
Preparation of YadC Polypeptide. The YadC polypeptide 
selected for testing in the present study Was a fragment of the 
YadC polypeptide of SEQ ID NO: 1. The fragment includes 
amino acid residues 137-409 of the amino acid sequence of 
SEQ ID NO: 1, Which are set forth in SEQ ID NO: 3. To 
produce GST-YadCl37_409 (Forrnan 2006), E. coli DHSO. con 
taining plasmid pGEX-YadCl37_409 Was groWn to an OD620 
of 0.5, IPTG Was added to a ?nal concentration of 1 .0 mM and 
the bacteria Were incubated for an additional 3 hours. Cells 
Were harvested by centrifugation at 4° C., and resuspended at 
0.05 the original volume in column buffer (20 mM Tris, 200 
mM NaCl, 1 mM EDTA pH 7.4). Samples Were passed tWice 
through a French press to lyse bacteria, cleared by centrifu 
gation at 9000><g for 30 minutes at 4° C., diluted 1:4 With 
column buffer and passed over a glutathione sepharose col 
umn. Bound protein Was eluted using column buffer contain 
ing 10 mM glutathione and collected in 1 mL aliquots. Purity 
Was assessed on SDS-PAGE gels stained With Coomasie bril 
liant blue. Protein-containing fractions Were pooled and dia 
lyzed, and the protein concentration measured by the bicin 
choninic acid assay (Pierce Chemical Co., Rockford, 111.). 
N-terminally His6-tagged LcrV (HT-LcrV) Was expressed 
in E. coli DHSO. from plasmid pHT-V and puri?ed on Talon 
metal-a?inity resin (Clonetech Laboratories, Inc, Palo Alto, 
Calif.) as described by Fields, 1999. 
Protection studies. Sets of 5 female outbred Swiss-Webster 
mice Were immunized subcutaneously With 40 ug amounts of 
puri?ed fusion proteins (GST-YadCl37_4O9, or HT-LcrV) or 
buffer emulsi?ed With ALHYDROGEL® (aluminum 
hydroxide gel) (Sigma Chemical Company, St. Louis, Mo.; 
6.25% vol/vol ?nal concentration) on days 0, 8, 14, and 22. 
On day 35, they Were challenged intravenously With 10,000 
CFU (5 LD50 doses) of Ypeszis CO99-3015.S7. 
Similarly, groups of 8 C57BL/ 6 mice Were immunized 
With 80 ug of HT-LcrV, GST-YadCl37_4O9, or GST (Sigma 
Chemical Company, St. Louis, Mo.) adjuvanted With ALHY 
DROGEL® as in the previous experiment. TWo Weeks after 
the 3rd immunization, the mice Were challenged intranasally 
With 3000 CFU ofCO92.S2 (6 times the LD50 dose) in BSL3 
conditions. 
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Determination of IgG isotypes. Measurement of antibody 
titer and isotype response Was performed by a modi?ed 
ELISA on serum samples taken 1 Week prior to bacterial 
challenge. 96-Well ELISA plates Were coated With 10 ug/ml 
of GST-YadCl37_4O9, HT-LcrV, GST or With buffer alone. 
Mouse sera Were then used at serial dilutions to a maximum 
dilution of 115,120,000. HRP conjugates against mouse IgG, 
IgG1, IgG2a, IgG2b, and IgG3 (BD Pharmingen, San Diego, 
Calif.) Were used as secondary antibodies. Protein-speci?c 
antibody titer Was estimated as the maximum dilution of 
serum giving an absorbance at 450 nm reading 0.1 units over 
the non-immunized mouse background sera (pre-immuniZa 
tion sera). Mean titers Were determined per treatment group. 
Human macrophages and cytokine analysis. The cytokine 
response of human peripheral blood monocytes (PBMs) to 
HT-LcrV, GST-YadCl37_4O9, and the negative control GST 
Was evaluated. Blood Was obtained from tWo healthy volun 
teers. Red blood cells Were lysed With ACK buffer (155 mM 
NH4Cl/l mM KHCO3/0.5 mM EDTA, pH 7.2), the samples 
Were Washed, and PBMs Were isolated by Ficoll-Paque den 
sity gradient. PBMs Were cultured for one Week in RPMI With 
12.5% human serum and 10 ug/ml of penicillin, streptomy 
cin, and neomycin at a concentration of 1><106 cells/ml in 5% 
CO2 to differentiate into macrophages. 
Differentiated PBMs Were stimulated With 10 pg of F1, 
HT-LcrV, GST, or GST-YadCl37_409 in 96-Well ELISA plates. 
100 pL of supernatant Was removed at 3 hours and then at 24 
hours. Supernatants Were kept at —800 C. until processed for 
cytokine analysis. All analyses Were done in triplicate in 2 
different experiments. Cytokine levels Were measured by 
Cytokine Bead Analysis (BDBiosciences) and evaluated by 
flow cytometry. 
Results 
yadC Operon and Predicted Properties of YadC. The 
adhesinYadA of the enteropathogenic yersiniae is encoded by 
the same Lcr plasmid that encodes LcrV. YadA contributes to 
colonization through binding to extracellular matrix compo 
nents such as ?bronectin, collagen, and laminin that in turn 
are bound to [31 integrins (Tahir E Y 2001; Hudson 2005). 
YadA belongs to a family of oligomeric coiled-coil (Oca) 
adhesins that are a subgroup of autotransporters composed of 
trimers With short outer membrane-anchor domains. The tri 
meric character may provide increased avidity for tight adher 
ence (HoicZyk 2000; Cotter 2005). Each YadA monomer is 
composed of an N-terminal head that contains a collagen 
binding motif, a neck that serves as a platform for the head 
and contributes to stability of the complex, a stalk composed 
of seven 15-mer units, a coiled-coil linker of tWo to three 
7-mer units that is necessary for transport of the head, neck, 
and stalk through the outer membrane, and a membrane 
anchor (HoicZyk 2000; Tahir EY 2001 ; RoggenkampA 2003; 
Nummelin H 2004). 
In I’. peslis, the yadA gene contains a frameshift mutation 
that prevents the expression of a functional YadA protein. To 
identify surface proteins of potential pathogenic importance 
for I’. peslis, We examined the I’. peslis CO92 genome for 
genes encoding proteins similar to YadA and identi?ed the 
1869 by ORF YPO1388 that Was subsequently named yadC. 
yadC is likely part of a bicistronic operon With the upstream 
1095 by ORF encoding another protein With homology to 
YadA and called yadB (YPO1387). yadBC is fairly isolated 
on the chromosome With the nearest gene upstream gene 300 
base pairs aWay and the nearest doWnstream gene 366 base 
pairs aWay. 
The yadB and yadC genes in the chromosome of I’. peslis 
CO92 also encode members of the Oca family (denoted as 
653a/b in ref (HoicZyk 2000)) and share the structural 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
14 
arrangement seen inYadA, although the amino-acid sequence 
similarity is not strong (FIG. 1). There is essentially no simi 
larity betWeen YadA and the tWo predicted I’. peslis proteins 
in the head regions.YadC is 25% identical and 45% similar in 
285 amino acids in the C-terminus of YadA. yadC encodes a 
putative 622 amino acid preprotein While yadB encodes a 
putative 364 residue preprotein. The predicted YadC protein 
(61 .6 kDa) has a much larger head domain than doesYadB (35 
kDa), Which carries only a short extension N-terminal to the 
neck domain. The isoelectric point of YadC is 4.0 While 
YadB’s PI is 4.5. BothYadB andYadC have signal sequences 
as found by SignalP 3.0 (Bendtsen 2004). These observa 
tions, considered With the yadBC bicistronic genetic arrange 
ment, suggest that YadB and YadC may function together. 
Importance of YadC for virulence in bubonic plague. 
Applicants have found that some human plague convalescent 
sera recogniZe YadC, and a yadBC mutant 1’. peslis has been 
found to shoW decreased adherence to epithelioid cells (For 
man 2006), suggesting that YadB and YadC might have a 
virulence role in plague. Further, the yadBC mutant Was 
attenuated from the subcutaneous route (mimicking bubonic 
plague) as compared to the virulent I’. peslis parent strain. 
This ?nding shoWs that yadBC encodes a neW virulence 
determinant for bubonic plague. This attenuation Was not 
demonstrated When mice Were challenged intranasally (mim 
icking pneumonic plague). 
Protection studies. One goal of the studies described herein 
is to obtain information useful for improving subunit plague 
treatment by identifying components that Will provide pro 
tection against pneumonic plague due to an F1- Ypeslis strain 
or against bubonic and systemic plague due to an F1+ strain. 
Since YadC Was determined to be a virulence factor for 
bubonic plague and is detectable by antibody. it likely is 
displayed on the bacterial surface Where it Would be acces 
sible to antibody. Therefore, its role as a protective antigen 
Was tested. TWo tests Were made for protective ef?cacy, using 
different challenge strains and infection routes. Mice Were 
immuniZed and challenged either intravenously or intrana 
sally, as outlined above. 
Negative-control mice received either ALHYDROGEL® 
only or GST-ALHYDROGEL® immuniZation. HT-LcrV-im 
muniZed mice Were used as the positive control. From an 
intravenous route, a test With SWiss-Webster mice challenged 
With 5 LD5O doses (10,000 CFU) of Ypeszis CO99-3015.S7 
revealed no protection for those immuniZed With buffer alone, 
full protection for HT-LcrV-immuniZed mice, and partial pro 
tection for GST-YadCl37_4O9-immuniZed mice (With 40% of 
mice surviving) (FIG. 2). After intranasal challenge, 87% of 
GST-YadCl37_409 C57BL/6 mice given 6 LD5O doses (3,000 
CFU) of Ypeslis CO99-3015.S9 survived pneumonic plague. 
This is compared to the GST control group (0 surviving mice) 
and the HT-LcrV-immuniZed group Where 50% survived the 
challenge (FIG. 3). There Was not a signi?cant difference in 
survival betWeen mice immuniZed With GST-YadCl37_409 or 
With HT-LcrV in either experiment; hoWever, there Was a 
signi?cant difference betWeen results for both proteins When 
compared to the GST- or ALHYDROGEL®-only negative 
control groups. Accordingly, YadC appears to be protective 
against F1- 1’. peslis from both intravenous and intranasal 
routes. This test also supports the prediction that YadC is 
accessible to antibody in vivo and is a true surface-localized 
protein. 
IgG isotypes. Protein-speci?c IgG1, IgG2A, and IgG2B, 
and IgG3 antibodies Were measured by ELISA in the sera of 
the mice immuniZed With GST-ALHYDROGEL®, GST 
YadCl37_409 or HT-LcrV. As has been reported, protection 
With the F1 -LcrV antigen is associated With predominantly a 
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Th2 IgG1 response (Williamson 1999). Likewise, in experi 
ments described herein, mice immunized With HT-LcrV dem 
onstrated a similar IgG isotype distribution 
(IgG1>IgG2a~IgG2b~IgG3, p<0.005 When IgG1 compared 
to other isotypes). Mice immunized WithYadC demonstrated 
a more balanced Th1/Th2 response 
(IgG1:IgG3>IgG2a>IgG2b, p<0.005 When IgG1 and IgG3 
compared to other isotypes). The total IgG titers to GST 
YadCl37_409 (1 :5.6><106) Were signi?cantly higher than those 
for HT-LcrV (1 :1><106) and total IgG titers to the GST com 
ponent in the negative control mice (1:6.4><105). 
Anti-in?ammatory/pro-in?ammatory cytokines. In 
response to stimulation With either GST-YadCl37_4O9, HT 
LcrV, or GST, PBMs produced little or no IL-10. PBMs 
stimulated With YadC shoWed a signi?cant TNF-ot and IL-6 
production that Was much higher than that due to LPS or 
HT-LcrV (FIG. 4). IL-12 production Was not detectable in 
response to either GST-YadCl37_409 or HT-LcrV (not shoWn) 
but a small amount of IL-1 Was produced in response to 
GST-YadCl37_409 but not to HT-LcrV. Overall, YadC pro 
vided more of a pro-in?ammatory response than did LcrV 
(i.e., increased IL-1 and IL-6). This ?nding suggests that a 
more balanced Th1/Th2 plague treatment composition is pos 
sible. An experiment Was also conducted using human alveo 
lar macrophages (AM) from bronchoalveolar lavage ?uid. 
This test revealed a different cytokine pro?le With signi? 
cantly more IL-10 produced in response to HT-LcrV than to 
GST-YadCl37_409 and signi?cant IL-12 production after 
stimulation With GST-YadC 137409 but not With HT-LcrV or 
GST alone (data not shoWn). Again, the overall picture Was 
that GST-YadCl37_409 Was more pro-in?ammatory and HT 
LcrV Was anti-in?ammatory. These different cytokine pro 
?les suggest that the antigens presented during bubonic and 
pneumonic plague have a very different immune effect. These 
data, combined With the previous challenge experiments, pro 
vide evidence that surface proteins like YadC Would be ben 
e?cial in inducing a more robust adaptive immunity response 
in future plague treatment compositions. 
Discussion. It is clear from previous studies (CoWan 2000) 
that I’. peslis has multiple adhesins and invasins to substitute 
for the absence of proteins such as YadA. These and other I’. 
peslis surface proteins could alter the current plague treat 
ment compositions to elicit a more balanced Th1/ Th2 pheno 
typic pro?le. Antigens, such as those identi?ed herein, are 
desirable for their ability to induce production of antibodies 
that can block crucial surface function such as epithelial 
adhesion and invasion. Ideally, genes for such crucial proteins 
could not be deleted from a potential bioterroristic Weapon 
Without loss of virulence, unlike F1. This study examined 1’. 
peslis YadC Which, as an acidic protein, could have a signi? 
cant impact on the bacterial surface and be important in 
ho st-patho gen interactions. 
A critical step in the clearance of pulmonary infections is 
the ability of the lung antigen-presenting cell to migrate to 
regional lymph nodes Where it can present the antigen to T 
cells to initiate an adaptive immune response. Previous stud 
ies have demonstrated a role for macrophage-lineage cells in 
mediating protection by anti-LcrV antibody in at least the 
liver (Philipovskiy A V 2004; CoWan C 2005; Philipovskiy 
2005). Recently it has been shoWn that When Lcr' I’. peslis 
Was given to mice intratracheally, the bacteria Were taken up 
by a characteristic population of DCs (CD11c"DEC2053O 
CD11b_) (Bosio C 2005). Data presented here suggest that 
PBMs When stimulated by a more favorable antigen (i.e., 
YadC) can participate in the induction of cytokines such as 
IL-1, TNF-ot, and IL-6 that Would favor development of adap 
tive Th1 cellular immunity in the lung and increased local 
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in?ammatory response. Additional pro-in?ammatory cytok 
ines fromAMs suggest thatYadC may play a role in recruiting 
additional innate immune cells such as natural killer cells to 
the lung environment. 
Finally, as YadC has shoWn to be required for virulence 
from a subcutaneous infection and is partially protective 
against pneumonic and systemic plague, it is believed that 
YadC polypeptides can be included in useful compositions 
for treating I’. Peslis infection. 
F1+ Subcutaneous Challenge and F1“ Intranasal Challenge 
of Subjects Treated With Composition Including Full-Length 
YadC Polypeptide. 
The folloWing is a prophetic example. Studies are con 
ducted to determine Whether subjects treated With a compo 
sition including the YadC polypeptide of SEQ ID NO: 1 are 
protected from: subcutaneous challenge With 1’. Peslis C092 
pCD2 Ap(res) F1", and intranasal challenge With 1’. Peslis 
C092 pCD2 Ap(res) F1“. 
For the study involving subcutaneous challenge, three 
groups of mice are provided. A test group is immuniZed With 
the composition including the YadC polypeptide of SEQ ID 
NO: 1, a positive control group is immuniZed With an HT 
LcrV composition, and a negative control group receives 
adjuvant alone (ALHYDROGEL®). I’. Peslis C099 F1+ cells 
are plated on HIB agar plates containing 2.5 mM CaCl2, 
0.10% xylose containing 50 ug/ml Cb (sHIBCZ750 agar), and 
Congo Red containing 50 ug/ml Cb (Congo Redcbso). Pig 
mentation (Pgm+) colonies are picked and placed into media. 
The sample is then vortexed and the concentration is deter 
mined by obtaining the 0D620 of a 1:20 dilution. Mice are 
anesthetiZed, and subcutaneously challenged With about 100 
cells/100 ul ofC099 F1+Ypestis. 
For the study involving intranasal challenge, three groups 
of mice are provided. A test group is immuniZed With the 
composition including the YadC polypeptide of SEQ ID NO: 
1, a positive control group is immuniZed With an HT-LcrV 
composition, and a negative control group receives adjuvant 
alone (ALHYDROGEL®). I’. Peslis C099 F1+ cells are 
plated on HIB agar plates containing 2.5 mM CaCl2, 0.10% 
xylose containing 50 ug/ml Cb (sHIBCl750 agar), and Congo 
Red containing 50 ug/ml Cb (Congo Redcbso). Pigmentation 
(Pgm+) colonies are picked and placed into media. The 
sample is then vortexed and the concentration is determined 
by obtaining the 0D620 of a 1:20 dilution. Mice are anesthe 
tiZed, and intranasally challenged With about 5000 cells/ 20 pl 
ofC099 131-1’. peslis. 
For the HT-LcrV-treated mice receiving subcutaneous 
challenge, no symptoms are observed, and there is an overall 
survival of 100%. For the mice treated With adjuvant alone, 
after subcutaneous challenge, there is a loW overall survival. 
For YadC (SEQ ID N0:1)-treated mice receiving subcutane 
ous challenge With C099 F1+I’. peslis, there is a protective 
effect, as compared to the mice receiving adjuvant alone. 
For the HT-LcrV-treated mice receiving intranasal chal 
lenge With C099 Fl'I’. peslis, no symptoms are observed, 
and there is an overall survival of 100%. For the mice treated 
With adjuvant alone, after intranasal challenge, there are no 
mice that survive. For YadC (SEQ ID N0:1)-treated mice 
receiving intranasal challenge With C099 Fl‘I’. peslis, there 
is a protective effect, as compared to the mice receiving 
adjuvant alone. 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 3 
<211> LENGTH: 622 
<212> TYPE: PRT 
<2l3> ORGANISM: Yersinia pestis 
<4oo> SEQUENCE: 1 
Met Asn Lys Glu Ile Lys Arg Met Gln Arg Met Gln Cys Ile Tyr Ile 
1 5 1o 15 
Ala Thr Trp Leu Ile Ala Val Phe Thr Ser Pro Ile Val Ile Ala Asn 
2o 25 3o 
Asn Thr Asn Ile Asn Gly Ser Thr Asn Asn Asn Gly Asn Gly Thr Ile 
35 4o 45 
Asn Ile Phe Asp Ala Ser Ser Asn Asn Asp Ile His Thr Leu Thr Gly 
50 55 6O 
Leu Gly Asn Glu Gln Leu Gly Gly Phe Ser Asn His Leu Ile Asp Ser 
65 7o 75 80 
His Asn Asn Thr Ile Asp Gly Gly Gln Ser Asn Asn Leu Val Ser Ser 
85 9o 95 
Asp Gly Asn Met Ile Ser Ala Ile Ser Leu Gly Asp Gly Leu Phe Tyr 
100 105 110 
Gly Ala Gln Asn Asn Thr Leu Ile Asn Ser Asn Asn Asn Leu Leu Ile 
115 120 125 
Val Thr Gln Gly Ser Thr Ile Ile Asp Ser Asp Ser Asn Thr Val Ser 
130 135 140 
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Gly 
145 
Glu 
Val 
Gly 
Ser 
Gly 
225 
Ser 
Asn 
Glu 
Ser 
Gly 
305 
Asn 
Gly 
Gly 
Asn 
Thr 
385 
Leu 
Glu 
Thr 
Ser 
Asn 
465 
Tyr 
Thr 
Leu 
Gln 
545 
Ile 
Asn 
Asp 
Ala 
Ser 
210 
His 
Glu 
Asn 
Asp 
Val 
290 
Asn 
Gly 
Asn 
Ile 
Ile 
Asp 
Asn 
Asn 
Thr 
Asn 
450 
Ile 
Tyr 
Thr 
Asp 
Thr 
530 
Lys 
Ser 
Ser 
Asn 
Leu 
195 
Val 
Tyr 
Asn 
Tyr 
Asn 
275 
Thr 
Ser 
Thr 
Asn 
Ala 
355 
Gly 
Thr 
Leu 
Ile 
Gly 
435 
Asn 
Tyr 
Met 
Asp 
Ser 
515 
Tyr 
Gln 
Asn 
Cys 
180 
Asn 
Asn 
Asn 
Asn 
Val 
260 
Ser 
Ala 
Thr 
Ser 
Ser 
340 
Leu 
Asp 
Ile 
Ser 
Asn 
420 
Glu 
Tyr 
Ala 
Ser 
Leu 
500 
Arg 
Ser 
Lys 
Asn 
Tyr 
165 
Asn 
Gly 
Asn 
Thr 
Val 
245 
Ile 
Ile 
Ile 
Gly 
Gly 
325 
Ala 
Gly 
Arg 
Asn 
Asn 
405 
Asn 
Tyr 
Thr 
Asp 
Asn 
485 
Ser 
Ile 
Asn 
Gln 
Leu 
150 
Ser 
Thr 
Leu 
Leu 
Ile 
230 
Thr 
Asp 
Leu 
Thr 
Ser 
310 
Asn 
Ser 
Ser 
Gln 
Val 
390 
Glu 
Tyr 
Thr 
Asp 
Glu 
Leu 
Val 
Asn 
Gly 
Leu 
550 
Ile 
Asp 
Leu 
His 
Met 
215 
Ser 
Asp 
Gly 
Gly 
Asn 
295 
Thr 
Asn 
Leu 
Gly 
Ile 
Ser 
Tyr 
Thr 
Asp 
Asn 
455 
Ser 
Ile 
Asn 
Glu 
Lys 
535 
Asn 
Glu 
Pro 
Ile 
Asn 
200 
Asp 
Gly 
Ser 
Asn 
Gly 
280 
Ser 
Leu 
Val 
Gly 
Ser 
360 
Thr 
Gln 
Ser 
Asp 
Asn 
440 
Gly 
Leu 
Asp 
Thr 
Tyr 
520 
Phe 
Ala 
Ser 
Ala 
Gly 
185 
Ser 
Thr 
Gly 
Thr 
Gly 
265 
Ser 
Val 
Thr 
Val 
Thr 
345 
Ile 
Ser 
Leu 
Asp 
Ala 
425 
Ser 
Met 
Leu 
Val 
Ile 
505 
Gln 
Gly 
Gly 
Asn 
Ser 
170 
Ser 
His 
His 
Gly 
Asp 
250 
Ile 
Gly 
Val 
Asp 
Asn 
330 
Gly 
Ala 
Val 
Asn 
Asn 
410 
Ser 
Ile 
Glu 
Ala 
Thr 
490 
Ile 
Arg 
Gly 
Ile 
Ser 
155 
Pro 
Asp 
Asn 
Asn 
Asn 
235 
Ala 
Gly 
Asn 
Phe 
Ser 
315 
Ile 
Ser 
Thr 
Lys 
Asp 
395 
Ser 
Leu 
Leu 
Ser 
Ile 
Leu 
Tyr 
Thr 
Phe 
Ala 
555 
Asn 
Ser 
Asn 
Asn 
Asn 
220 
Asn 
Asn 
Arg 
Met 
Gly 
300 
Val 
Gly 
Val 
Arg 
Lys 
380 
Ser 
Phe 
Asp 
Leu 
Val 
460 
Tyr 
Asn 
Thr 
Phe 
Asp 
540 
Ala 
Ile 
Gly 
Asn 
Asp 
205 
Ile 
Asp 
Ile 
Asp 
Gly 
285 
Gly 
Ser 
Gly 
Ser 
Asn 
365 
Gly 
Phe 
Ser 
Thr 
Val 
445 
Ser 
Asn 
Asn 
Gly 
Lys 
525 
Lys 
Thr 
Ile 
Ala 
Thr 
190 
Ile 
Ile 
Ile 
Asn 
Asp 
270 
Val 
Asn 
Val 
Ala 
Ser 
350 
Asp 
Val 
Asp 
Thr 
Val 
430 
Thr 
Asn 
Glu 
Ala 
Lys 
510 
Asn 
Asp 
Met 
Gly 
Trp 
Ile 
Ile 
Ala 
Phe 
Gly 
255 
Leu 
Gly 
Thr 
Ser 
Ala 
335 
Glu 
Glu 
Glu 
Asp 
Val 
415 
Leu 
Asn 
Tyr 
Glu 
Asn 
495 
Gln 
Glu 
Ile 
Ala 
Asn 
160 
Cys 
Thr 
Ala 
Gly 
Gly 
240 
Ser 
Thr 
Asp 
Ser 
Gly 
320 
Asn 
Gly 
Leu 
Asn 
Val 
400 
Thr 
Asn 
Glu 
Ala 
Ala 
480 
Asn 
Tyr 
Phe 
Asn 
Ala 
560 
23 
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Ala 
Leu 
Gln 
Val 
Ala 
Val 
Arg 
565 
Gly Tyr Ser 
580 
Asn Gln Arg 
595 
Gly Val Ser 
610 
SEQ ID NO 2 
LENGTH: 1869 
TYPE: DNA 
Ile Pro Gln Lys 
Asp 
Ile 
Leu 
Ser 
Gln 
Thr 
Leu 
615 
Gly Ser 
Gly Ala 
585 
Met 
600 
Asn 
Thr Gly 
ORGANISM: Yersinia pestis 
SEQUENCE: 2 
atgaataagg aaattaaacg 
atcgcagtat 
aataataacg 
acactaaccg 
cataataata 
atcagcgcca 
aactcaaaca 
aatactgtgt 
gaaaatagtt 
aatacgctca 
agtcataaca 
attatcgcgg 
agtgaaaaca 
atagatggga 
tctggcaata 
ggtaatacat 
aacggtacat 
gctagcttag 
attgctacac 
ggtgttgaga 
ctgaatttat 
aattatactg 
tcaatattat 
agtaattatg 
aattacatgt 
tcagttaata 
caacgtactt 
aaagatatta 
gcggttattc 
agcgatcaag 
ttacttcgcc 
gtaatggtac 
gtcttggtaa 
cgatagacgg 
ttagcttggg 
acaacctact 
ctggcattag 
gttattcgga 
ttggcagtga 
atgatattat 
gagggcacta 
atgttactga 
atggaattgg 
ctggtaattc 
cggggaataa 
gtacaggctc 
ggaatgatga 
atacagatac 
caaatgaata 
atgcctcatt 
tggttactaa 
caaatatcta 
ctaatcttat 
ccattatata 
ttaaaaatga 
atcaaaagca 
ctcaaaaatc 
gcgcaggatc 
gatgcaacgg 
gatagtgata 
aatcaatatt 
tgagcagttg 
tggtcagagt 
cgatggcctc 
tattgtcact 
taataatctt 
tcccgcgtcc 
taacaatacg 
tgctagctct 
caacaccatt 
cagcaccgac 
tcgagatgat 
ggattcagta 
aaccggctcc 
tgtcgttaat 
ggtatcctct 
actgaatatc 
aatcaatgtt 
ttctgacaac 
agatactgtg 
tgaaagcaat 
tgctgatgaa 
agatgtgacg 
taccggaaaa 
atttttaacc 
gaaacaatta 
gggttctaaa 
tgtgggagcg 
Lys Val 
5'70 
Gly Ser 
Thr Thr 
Leu Ser 
atgcaatgca 
gctaacaata 
tttgacgcca 
ggaggattta 
aacaacctgg 
ttctacggcg 
cagggcagta 
atagagagca 
ccatcaggag 
atcactggtg 
gtaaataatt 
51911991199119 
gccaatatca 
ttgactgaag 
accgcgatta 
actctgacag 
atcggcggag 
gaaggaggaa 
ggtgatagac 
agtcagttaa 
tctttttcca 
ttgaatacaa 
aattatactg 
tctttgttag 
ttaaataatg 
caatatacag 
tattctaatg 
aacgcgggaa 
gtctctattg 
atttggcatg 
Ser Ile Gly 
Val Gly Ala 
590 
Met Thr Tyr 
605 
Ile Gly Ile 
620 
tatatatcgc 
cgaatattaa 
gcagtaataa 
gtaatcatct 
taagtagcga 
cgcagaataa 
ctataataga 
acagcaatat 
cgtggtgcgt 
cgctgaatgg 
taatggatac 
gaaacaatga 
atggtagtaa 
ataactctat 
ccaatagcgt 
attctgtatc 
cggcaaacgg 
ttgcattggg 
aaattaccag 
acgatagctt 
ctgtcactga 
ctggtgaata 
acaatggcat 
ctatctataa 
ctaataacta 
actctcgaat 
gaaaatttgg 
tagcggcgac 
gtgtcgggct 
taaatcaacg 
Val Gly 
575 
Ile Trp 
Asp Thr 
cacttggtta 
tggcagtacc 
cgatattcat 
tatcgactct 
tggcaatatg 
cacgttaata 
ttctgatagt 
tatcggtaat 
tgacaatcaa 
tcttcacaac 
gcataataat 
catttttggg 
taactacgtg 
attgggcggc 
ggtgttcggc 
ggttagcggc 
taataatagt 
tagcggttcg 
cgttaaaaaa 
tgatgatgtt 
aaatataaat 
taccgacaac 
ggagagtgtt 
tgaagaggct 
tactgatctt 
caatgagtac 
cggttttgat 
gatggctgct 
tgcaggatat 
aatcacaatg 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1740 
1800 
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—cont inued 
aatacaacga tgacttacga tactcaacgt ggtgttagtt tattaacggg tttatctatc 1860 
ggcatatga 1869 
<2lO> SEQ ID NO 3 
<2l2> TYPE: PRT 
<2l3> ORGANISM: Yersinia pestis 
<400> SEQUENCE: 3 
Asp Ser Asp Ser Asn Thr Val Ser Gly Ile Ser Asn Asn Leu Ile Glu 
1 5 1O 15 
Ser Asn Ser Asn Ile Ile Gly Asn Glu Asn Ser Cys Tyr Ser Asp Pro 
20 25 3O 
Ala Ser Pro Ser Gly Ala Trp Cys Val Asp Asn Gln Asn Thr Leu Ile 
35 4O 45 
Gly Ser Asp Asn Asn Thr Ile Thr Gly Ala Leu Asn Gly Leu His Asn 
5O 55 6O 
Ser His Asn Asn Asp Ile Ile Ala Ser Ser Val Asn Asn Leu Met Asp 
65 7O 75 8O 
Thr His Asn Asn Ile Ile Ala Gly Gly His Tyr Asn Thr Ile Ser Gly 
85 9O 95 
Gly Gly Asn Asn Asp Ile Phe Gly Ser Glu Asn Asn Val Thr Asp Ser 
100 105 110 
Thr Asp Ala Asn Ile Asn Gly Ser Asn Asn Tyr Val Ile Asp Gly Asn 
115 120 125 
Gly Ile Gly Arg Asp Asp Leu Thr Glu Asp Asn Ser Ile Leu Gly Gly 
130 135 140 
Ser Gly Asn Met Gly Val Gly Asp Ser Val Thr Ala Ile Thr Asn Ser 
145 150 155 160 
Val Val Phe Gly Gly Asn Thr Ser Gly Asn Ser Thr Gly Ser Thr Leu 
165 170 175 
Thr Asp Ser Val Ser Val Ser Gly Asn Gly Thr Ser Gly Asn Asn Val 
180 185 190 
Val Asn Ile Gly Gly Ala Ala Asn Gly Asn Asn Ser Ala Ser Leu Gly 
195 200 205 
Thr Gly Ser Val Ser Ser Glu Gly Gly Ile Ala Leu Gly Ser Gly Ser 
210 215 220 
Ile Ala Thr Arg Asn Asp Glu Leu Asn Ile Gly Asp Arg Gln Ile Thr 
225 230 235 240 
Ser Val Lys Lys Gly Val Glu Asn Thr Asp Thr Ile Asn Val Ser Gln 
245 250 255 
Leu Asn Asp Ser Phe Asp Asp Val Leu Asn Leu Ser Asn Glu Tyr Ser 
260 265 270 
Asp 
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What is claimed is: 
1. A composition for inducing an immune response in a 
subject, comprising a fusion protein including GST and 
amino acid residues 137-409 ofYadC (SEQ ID NO: 3). 
2. The composition of claim 1, Wherein the composition 
induces an immune response against Fl-positive and 
Fl-negative strains of 1’. peslis. 
3. The composition of claim 1, Wherein the composition 
induces an immune response against E 1 -negatiVe strains of 1’. 
peslis. 
4. A method of inducing an immune response in a subject, 
comprising: introducing into the subject a composition of 
claim 1. 
5. The method of claim 4, Wherein the composition induces 
an immune response against Fl-positive and Fl-negative 
strains of 1’. peslis. 
6. The method of claim 4, Wherein the composition induces 
an immune response against Fl-negative strains of 1’. peslis. 
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7. The method of claim 4, Wherein the subject is in need of 
treatment for a 1’. peslis infection. 
8. The method of claim 4, Wherein the subject is susceptible 
to 1’. peslis infection. 
9. A composition for inducing an immune response in a 
subject, comprising: a fusion protein comprising: a fragment 
of the YadC polypeptide consisting of amino acid residues 
137-409 ofYadC (SEQ ID NO: 3); and additional amino acids 
at the N-terminal and/ or C-terminal end of the fragment (SEQ 
ID NO: 3) that differ from those amino acids present in the 
YadC polypeptide (SEQ ID NO: 1). 
10. A composition for inducing an immune response in a 
subject, comprising: an isolated polypeptide molecule con 
sisting of amino acid residues 137-409 ofYadC (SEQ ID NO: 
3). 
